IPSC
Century Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$406.17M
P/E Ratio
—
EPS
$-0.15
Beta
1.67
52W High
$3.04
52W Low
$0.40
50-Day MA
$2.20
200-Day MA
$1.06
Dividend Yield
—
Profit Margin
-8.78%
Forward P/E
—
PEG Ratio
—
About Century Therapeutics Inc
Century Therapeutics Inc. (Ticker: IPSC) is a pioneering biotechnology company dedicated to advancing allogenic cell therapies that aim to revolutionize cancer treatment. Leveraging its proprietary induced pluripotent stem cell (iPSC) technology, the company is developing innovative off-the-shelf therapeutic solutions designed to improve both patient outcomes and accessibility. With a strong pipeline of clinical-stage product candidates and strategic collaborations enhancing its competitive advantage, Century Therapeutics is well-positioned to drive innovation in the rapidly expanding cell therapy landscape, presenting compelling potential for clinical breakthroughs and favorable shareholder returns.
Fundamentals
| Revenue (TTM) | $109.16M |
| Gross Profit (TTM) | $13.50M |
| EBITDA | $-1.94M |
| Operating Margin | -13.80% |
| Return on Equity | -5.98% |
| Return on Assets | -3.26% |
| Revenue/Share (TTM) | $1.26 |
| Book Value | $1.82 |
| Price-to-Book | 2.40 |
| Price-to-Sales (TTM) | 3.72 |
| EV/Revenue | 2.817 |
| EV/EBITDA | 118.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $179.72M |
| Float | $97.53M |
| % Insiders | 12.83% |
| % Institutions | 58.74% |
Analyst Ratings
Consensus ($3.00 target)
1
Strong Buy3
Buy1
HoldData last updated: 4/8/2026